



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU3517USW		SERIAL NO. 10/070,084	
				APPLICANT Andrews et al.		GROUP 1624	
				FILING DATE 03/01/02			
U.S. PATENT DOCUMENTS							
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
VER	AC	5,945,450	Takenouchi, et. al.	514	535		
VER	AD	5,719,143	Badore, et al.	514	221		
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	
VER	BC	EP 0667344A1	13 Feb. 1995	EPO		English abstract	
VER	BD	WO 93/15043	8 May 1993	PCT		English abstract	
VER	BE	JP 59 181246	1984-10-15	JP		English abstract	
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
VER	CE	De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," <i>Il Farmco</i> , 1999, Vol. 54, pgs 26-45.					
VER	CF	Balzarini, "Suppression of Resistance to Drugs Targeted to Human Immunodeficiency Virus Reverse Transcriptase by Combination Therapy," <i>Biochemical Pharmacology</i> , 1999, Vol: 58, p: 1-					
VER	CG	Inaba, et. al., "Benzodiazepines. V. A Novel Synthesis of a 7-Nitro-1,4-benzodiazepine Derivative," <i>Chem. Pharm. Bull.</i> , 1971, Vol. 19, p. 722.					
Continue on page _____							
EXAMINER 				DATE CONSIDERED 2/9/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

BEST AVAILABLE COPY

BEST AVAILABLE COPY